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Background: Axillary lymph node (ALN) status is an important prognostic factor for breast cancer. We retrospectively
used contrast-enhanced computed tomography (CE-CT) to evaluate the presence of ALN, metastasis based on size,
shape, and contrasting effects.
Methods: Of 131 consecutive patients who underwent CE-CT followed by surgery for breast cancer between 2005 and
2012 in our institution, 49 were histologically diagnosed with lymph node metastasis. Maximum Hounsfield units (HU)
and mean HU were measured in non-contrasting CT (NC-CT) and CE-CT of ALNs.
Results: Of 12 examined measurements, we found significant differences between negative and metastatic ALNs in
mean and maximum NC-CT HU, and mean and maximum CE-CT HU (P < 0.05). We used a receiver operating curve, to
determine cut-off values of four items in which significant differences were observed. The highest accuracy rate was
noted for the cut-off value of 54 as maximum NC-CT HU for which sensitivity, specificity, and accuracy rate were 79.6%,
80.5% and 80.2%, respectively.
Conclusions: CT HU of a patient with breast cancer are absolute values that offer objective disease management data
that are not influenced by the screener’s ability.
Keywords: Breast cancer, Computed tomography, Hounsfield unit, Lymph node metastasis, Diagnosis,
Axillary lymph nodeBackground
Breast cancer is the most common newly diagnosed cancer
type and the fifth most common cause of cancer-related
death among women in Japan [1]. Status of axillary
lymph nodes (ALNs) is the most important predictor
of survival [2].
Manual palpation is a well-known method that is used
to non-invasively detect ALN metastasis [3]; however, it
has low specificity and sensitivity and cannot accurately
predict the ALN status [4]. Contrast-enhanced computed
tomography (CE-CT) has been used to evaluate ALN* Correspondence: ykijima@m3.kufm.kagoshima-u.ac.jp
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[5-10]. Use of whole-body 18 F-fluorodeoxy glucose-
positron emission tomography (FDG-PET)/CT for breast
cancer staging and treatment monitoring has also recently
increased due to its ability to detect previously unknown
metastases [11-16]. However, its diagnostic accuracy for
ALN staging has not yet been established [16,17].
Hounsfield units (HU) are a measure of X-ray attenuation
in CT images. This retrospective study evaluated ALN
metastasis against HU to determine optimal cut-off values.Methods
Patients
Between January 2005 and May 2012, 283 consecutive
patients with invasive ductal carcinoma (IDC) underwent
breast and axillary surgery in our hospital without anytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Clinical characteristics of the 131 patients
Variable













Total mastectomy 74 (56.5%)
Partial mastectomy 57 (43.5%)
Lymph node dissection
SNB* without axillary lymphadenectomy 42 (32.1%)
SNB* with axillary lymphadenectomy 9 (6.9%)




*Sentinel lymph node biopsy.
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endocrine therapy. Of these patients, 131 underwent
CE-CT prior to surgery in our hospital using the same
system, and were enrolled in this study; the other 152
patients underwent CE-CT using a different system in
another hospital. All subjects had undergone mam-
mography, ultrasonography (US), core needle biopsies
for their primary breast lesions, bone scintigraphy for
preoperative staging. Magnetic resonance imaging, FDG-
PET, and pathological or cytological examinations for
ALNs, depending on the case. Sentinel lymph node (SLN)
biopsies were performed on 51 patients with diagnoses of
clinical T1N0M0 breast cancer according to the TNM
classification [18]. The dye and radioisotope method used
to detect SLNs was reported previously [19]. Axillary
lymphadenectomy was performed on 27 and 18 patients
who were diagnosed with T1-4N1M0 or T2-4N0M0,
respectively. Of 51 patients who underwent SLN
biopsies, 9 received additional axillary lymphadenec-
tomy due to findings of metastasis by the intraoperative
histological examination.
Patient characteristics and the pathological and surgical
findings were collected from our database records and
individual patient electronic medical records, and was
approved by the Institutional Review Board of the
Kagoshima University Medical and Dental Hospital. We
received informed consent from each study participant
and approval for our protocol from the Ethics Committee
of Kagoshima University.
Table 1 shows clinicopathological features of the 131
patients enrolled in this study. Their average age was
58.3 years (range: 21–95 years). One patient was diagnosed
with T1mic cancer, 73 with T1, 32 with T2, 7 with T3, and
18 with T4 lesions. Total and partial mastectomies were
performed on 74 and 57 patients, respectively. SLN biopsy
was performed on 42 patients, SLN biopsy followed by
axillary lymphadenectomy on 9 patients, and axillary
lymphadenectomy on 80 patients. Of the 131 patients,
49 had lymph node metastasis. All metastases were evalu-
ated as macrometastasis (Table 1).
Testing set
All 95 consecutive patients with IDC who underwent
breast and axillary surgery in our hospital between June
2012 and July 2014 with no neoadjuvant therapy under-
went CE-CT: 40 before surgery in our hospital using the
same system, and the other 55 patients using a different
system in another hospital. We enrolled the 40 former
patients in this testing set.
CT scanning
Patients were examined in a supine position with their
arms stretched above their heads at the end of inspiration
using a CT scanner (Aquilion TM64, Toshiba Medical,Tokyo, Japan). Scanning parameters included 120 kVp, a
0.5-second tube rotation, 53° helical pitch, 206-mm table
speed, 0.5 second gantry rotation time, and 3-mm thick
reconstructed sections. Images were analyzed on SYN-
APSE (Fuji Film, Inc., Tokyo, Japan).
We observed 437 ALNs in 131 patients on CT. On
some slides, in which both the pectoralis major and
minor muscles were detected, we evaluated all lymph
nodes without any information on pathological findings.
The mean number of evaluated lymph nodes in each
patient was 3.34 (range: 2–6). Maximum and mean HU
were measured in non-contrasting CT (NC-CT) and
CE-CT ALNs, contralateral ALNs, the aortic inside
arch and the pectoralis major muscle. To measure
lymph node HU with/without internal fat at normal
lymph node hila, we traced outlines of lymph nodes by
hand to highlight a range of interest (ROI) (Figure 1).
To exclude artificial contamination, we excluded these
outlines when we evaluated mean HU values, but included
them to determine maximum HU values. On each lymph
node, we also evaluated long- and short-axis diameters,
and internal fat density, which indicated absence of central
images for bilateral ALNs. The highest value of a patient’s





Figure 1 Measurement of axillary lymph nodes in a patient with invasive ductal carcinoma in the left breast. A. ALN sizes were
measured in the maximum sectioned surface of the CT image with 3-mm slices: (1) Longest transverse diameter of the oval lymph node; (2)
Shortest transverse diameter of the oval lymph node; B. To measure mean HU, we selected a range of interest (ROI) such that the line did not
protrude from the ALN edge. C. ROI surrounded the lymph node, and the maximum HU inside of the ROI was measured. We took extra care not
to include bone or blood vessels near the ROI.
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simultaneously determined in the same manner.
Pathological evaluation
All dissected ALNs were cut into single sections and
stained with hematoxylin–eosin for analysis by a patholo-
gist. Both micro- and macro-metastasis were considered
positive.
Statistical analysis
Data were evaluated using SPSS Ver.20 software (IBM
SPSS, Chicago, IL). Student’s t-test was used to assess
differences between the groups. P < 0.05 was considered
significant. We examined mean HU and maximum HU
of the ALNs and primary tumor on both NC-CT and
CE-CT. We examined differences between metastatic
lymph nodes and non-metastatic lymph nodes using 18
measurements, as shown in Table 2. We then used the
Youden index of receiver operating characteristic (ROC)
curve to determine cut-off values for items in which asignificant difference was observed in the t-test. The ROC
curve was drawn using SPSS Ver.20 software (Figure 2,
for an example).
Results
HU value and lymph node metastasis
Mean NC-CT HU was 7.83 ± 22.31 for non-metastatic
lymph nodes and 29.17 ± 16.37 for positive nodes. Simi-
larly, maximum NC-CT HU, mean CE-CT HU, and
maximum CE-CT HU were 34.28 ± 23.58, 60.06 ± 17.52
and 52.45 ± 27.29 for negative nodes; and 78.09 ±
22.49, 86.95 ± 27.58 and 118.63 ± 23.14 for positive
nodes, respectively (Table 2). We also analyzed associ-
ations between pathological findings for metastasis and
NC-CT and CE-CT HU values for ALNs, primary tumors,
and long- and short-axis diameters (Table 2).
Of the 12 values, mean ALN NC-CT HU, maximum
ALN NC-CT HU, mean ALN CE-CT HU, maximum
ALN CE-CT HU, long- and short-axis ALN diameters,
and long- and short-axis diameters of the primary tumor
Table 2 Comparisons between negative and positive lymph nodes for 12 CT measurements
Lymph node metastasis
Factors (mean ± SD) Negative (n = 82) Positive (n = 49) P
Mean NC-CT HU of lymph node 7.83 ± 22.31 29.17 ± 16.37 < 0.05
Maximum NC-CT HU of lymph node 34.28 ± 23.58 60.06 ± 17.52 < 0.05
Mean CE-CT HU of lymph node 52.45 ± 27.29 78.09 ± 22.49 < 0.05
Maximum CE-CT HU of lymph node 86.95 ± 27.58 118.63 ± 23.14 < 0.05
Mean NC-CT HU of primary tumor 36.09 ± 18.88 37.28 ± 16.58 0.89
Maximum NC-CT HU of primary tumor 69.30 ± 30.65 78.17 ± 18.55 0.11
Mean CE-CT HU of primary tumor 91.92 ± 28.36 89.03 ± 31.45 0.39
Maximum CE-CT HU of primary tumor 135.81 ± 31.27 148.88 ± 25.32 0.88
Long-axis diameter of lymph node (mm) 6.05 ± 2.32 10.37 ± 4.75 < 0.05
Short-axis diameter of lymph node (mm) 4.42 ± 1.71 7.35 ± 3.39 < 0.05
Long-axis diameter of primary tumor (mm) 18.71 ± 10.14 40.54 ± 37.94 < 0.05
Short-axis diameter of primary tumor (mm) 12.99 ± 7.11 25.44 ± 33.37 < 0.05








Figure 2 ROC curve of maximum HU of an unenhanced lymph node CT. The AUC of this case was 0.827. We made a ROC curve and found
the cut-off value using the Youden index.
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with maximum and mean HU significantly higher in
positive nodes. However, in the primary tumors, none of
the CT values correlated with ALN metastasis (Table 2).
Lymph node metastasis and diameters of the lymph node
and primary tumor
Long- and short-axis diameters of metastatic lymph nodes
were significantly larger than for negative nodes (P < 0.05,
Table 2). Long- and short-axis diameters of primary tumors
correlated with lymph node metastasis (P < 0.05 for both).
Diagnostic accuracy of HU values in detecting lymph
node metastasis
For the four items with significantly higher HU values in
metastatic lymph nodes—mean and maximum NC-CT
HU values, and mean and maximum CE-CT HU values
(Table 3)—we determined HU cut-off values, using the
Youden index for ROC curves (Figure 2). The highest
accuracy rate was found for maximum ALN NC-CT HU
at a cut-off value of 54 (sensitivity: 79.6%; specificity:
80.5%; positive predictive value [PPV]: 70.9%; negative
predictive value [NPV]: 86.8%; accuracy: 80.2%), followed
by maximum ALN CE-CT HU at a cut-off value of 103
(sensitivity: 83.7%; specificity: 72.0%; PPV: 64.1%; NPV:
88.1%; accuracy: 76.3%), and mean ALN CE-CT HU at a
cut-off value of 16 (sensitivity: 83.7%; specificity: 64.6%;
PPV: 58.6%; NPV: 86.9%; accuracy: 71.8%). In the same
way, we determined size cut-off values and listed sensitivity,
specificity, PPV, NPV, and accuracy (Table 4).
Evaluations of testing set
We used cut-off values for mean and maximum HU
values of both NC-CT and CE-CT which were derived
from 131 cases, to evaluate several lymph nodes in one
patient, which we compared with pathologists’ findings,
as shown in Table 5.
Discussion
The 10-year survival rate of patients with ALN metastasis




Mean HU 16 83.7
Maximum 54 79.6
Lymph node CE-CT
Mean HU 60 85.7
Maximum HU 103 83.7
CE-CT: contrast-enhanced computed tomography; HU: Hounsfield unit; NC-CT: non-con
predictive value.from 30% for those with > 10 metastases to 90% for those
with no metastasis [2]. The ALN status is not only im-
portant for estimating prognoses, but also for selecting
individual treatment regimens [20]. The American College
of Surgeons Oncology Group (ACOSOG) Z0011 trial
showed that patients randomized to SLN dissection
(SLND) alone or to SLND + ALN dissection (ALND),
did not significantly differ in local or regional recur-
rence [21]. The ACOSOGZ0011 enrolled patients who
were diagnosed as N0 before randomization, which sup-
ports the importance of preoperative ALN evaluation.
Our present study could facilitate these evaluations.
The use of CT to assess ALN metastasis has been re-
ported previously [5-10]. Relatively good results were
reported for various criteria used to detect lymph node
metastasis, such as short-axis ALN diameter, ratio of
long- to short-axis ALN diameters, enhancement type,
shape, or intra-nodal fat density [10,22-24]. Such methods
are useful for detecting ALN metastasis, but may strongly
depend on the personal ability of the screener.
Use of US in diagnosing ALN metastasis is also widely
reported [25,26]. Results of US for non-palpable axillary
nodes based on nodal size showed that sensitivity varied
between 48.8% (95% confidence interval: 39.6–58%) and
87.1% (76.1–94.3%) and specificity varied between 55.6%
(44.7–66.3%) and 97.3% (86.1–99.9%); for lymph node
morphology, sensitivity ranged from 26.4% (15.3–40.3%)
to 75.9% (56.4–89.7%) and specificity ranged from 88.4%
(82.1–93.1%) to 98.1% (90.1–99.9%) [25]. We previously
reported that US screening of ALNs was useful both for
diagnosing nodal metastasis, and for predicting prognoses.
We showed that US sensitivity, specificity and accuracy
rates were 69.5%, 85.8% and 79.7%, respectively [26];
however, its ease of use is somewhat offset by the influ-
ence of operator’s skill and possible subjectivity, whereas
measuring CE-CT HU is a simple, easy method that does
not depend on the physician’s skill.
In a voxel with average linear attenuation coefficient
μx, the corresponding HU value is given by: HU =
1000 × (μx − μwater)/μwater − μair where μwater and μair are
the linear attenuation coefficients of water and air; i.e.,tatic and negative lymph nodes
Specificity PPV NPV Accuracy
(%) (%) (%) (%)
64.6 58.6 86.9 71.8
80.5 70.9 86.8 80.2
58.5 55.3 87.3 68.7
72 64.1 88.1 76.3
trasting computed tomography; NPV: negative predictive value; PPV: positive
Table 4 Size measurements that differed significantly in metastatic and negative lymph nodes
Cut-off value Sensitivity Specificity PPV NPV Accuracy
(mm) (%) (%) (%) (%) (%)
Lymph node
Long-axis dia 7.42 75.5 74.4 63.8 83.6 74.8
Short-axis dia 4.96 81.6 73.2 64.5 87 76.3
Primary tumor
Long-axis dia 17.08 91.7 56.1 91.7 56.1 69.2
Short-axis dia 16.27 57.1 81.7 65.1 76.1 72.5
Dia: diameter; NPV: negative predictive value; PPV: positive predictive value.
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attenuation of radiation in water. Positive values represent
tissues with attenuation values higher than that of water
and negative values represent tissues with lower values.
The number 1000, sometimes called the magnifying value,Table 5 Testing set results for lymph node metastases; CT
values compared with pathological findings
Mean NC-CT HU Pathological findings
Positive Negative Total
CT† Positive 9 9 18
Negative 1 21 22
Total 10 30 40
Sensitivity 90.0%, Specificity 70.0%, PPV 50.0%, NPV 95.5%,
Accuracy 75.0%
Maximum NC-CT HU Pathological findings
Positive Negative Total
CT† Positive 10 7 17
Negative 0 23 23
Total 10 30 40
Sensitivity 100.0%, Specificity 76.7%, PPV 58.8%, NPV 100.0%,
Accuracy 82.5%
Mean CE-CT HU Pathological findings
Positive Negative Total
CT† Positive 7 13 20
Negative 3 17 20
Total 10 30 40
Sensitivity 70.0%, Specificity 56.7%, PPV 35.0%, NPV 85.0%,
Accuracy 60.0%
Maximum CE-CT HU Pathological findings
Positive Negative Total
CT† Positive 8 12 20
Negative 2 18 20
Total 10 30 40
Sensitivity 80.0%, Specificity 60.0%, PPV 40.0%, NPV 90.0%,
Accuracy 65.0%
†Diagnosis of metastasis through CT HU values.
CE-CT: contrast-enhanced computed tomography; HU: Hounsfield unit; NC-CT:
non-contrasting computed tomography; NPV: negative predictive value; PPV:
positive predictive value.is incorporated into the above equation to expand the
scale sufficiently to provide whole number attenuation
values [27]. Mean HU can be influenced by ROI selection,
whereas maximal HU does not vary with ROI placement.
Although selecting an ROI cannot currently be automated
or standardized, it is an easy manual skill that requires no
special technique or software. However, neighboring
structures (e.g., bone or blood vessels) should be carefully
avoided in selecting a ROI, as maximum HU markedly
changes when structures other than lymph nodes are
included. Further study is needed to clarify the accuracy of
segmentation for ROI delineation; such investigation
might show how much of a learning curve exists to
acquire the stable ability to determine the HU value by
non-experts. We found sensitivity, specificity, PPV,
NPV, and accuracy were 79.6%, 80.5%, 70.9%, 86.8%,
and 80.2%, respectively, at a cut-off value of 54 for
maximum NC-CT HU. As this result was superior to
the findings of previous studies [11,17,25], clinical use
of this cut-off value is feasible. Furthermore, accuracy
rates were 76.3%, 71.8%, and 68.7% for maximum CE-CT
HU, mean NC-CT HU, and mean CE-CT HU, respect-
ively. Therefore, the maximum NC-CT HU cutoff appears
adequate to estimate ALN metastasis. Our results showed
that NC-CT effectively detected metastasis, and is clearly
superior to CE-CT and PET-CT, even from the viewpoint
of side effects and cost. In any case, we recommend that
HU be measured to evaluate lymph node metastasis when
deciding preoperative staging.
The testing set results under blind conditions validated
the analysis. The cut-off value for maximum NC-CT HU
showed sensitivity, specificity, PPV, NPV, and accuracy
of 100.0%, 76.7%, 58.8%, 100.0%, and 82.5%, respect-
ively, which is particularly useful in light of how easily
obtainable this measurement is in routine preoperative
examinations.
To our knowledge, this is the first study to show that
metastatic and negative ALNs differ in their mean and
maximum HU values. Metastases that contain tumor
cells, vascularization, or immune reactions within lymph
nodes may elevate HU values. Although we did not
evaluate the relationship between metastatic area and
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this issue.
This study had three limitations. First, maximum HU
may measure artifacts [28], and no conclusive evidence
currently shows that maximum HU can accurately assess
ALN metastasis. We also examined HU in 3-mm CT
slices in this study; however, HU values on image borders
may be inaccurate for small structures such as lymph
nodes due to the partial volume effect. Secondly, HU
values depend on the CT machine, imaging conditions,
and specifications of the image processing software,
which differ in every institution, and may vary due to
maintenance or an update. A cut-off value for HU in
detecting ALN metastasis may only apply to selected
patients who undergo NC-CT screening in the same
institution. Thus, cut-off values should be regularly
recalibrated before treating patients. Finally, comparing
one-to-one correspondences between resected lymph
nodes and CT ALN images in the present retrospective
study was difficult. Confirming relationships between
preoperative CT HU and intraoperative and postoperative
histological evaluations should resolve these problems. We
will be able to achieve higher accuracy by measuring
several ALNs followed by the selection of one node with
the highest HU value.Conclusions
In conclusion, we have shown that measuring the max-
imum HU is a simple, easy, and useful technique for
diagnosing ALN metastasis in breast cancer patients.
However, as this was a retrospective study with rela-
tively few patients, our results should be verified by a
blinded prospective investigation by several researchers
and a larger cohort.
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